14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
PYPD vs ADXN
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
PYPD vs ADXN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PYPD Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–1 Matrix Metrics)
PYPD Overall Winner
6-Pillar Tally: PYPD 4 – 1 ADXN (1 Tie)
Matrix Metrics: PYPD 6 – 1 ADXN
As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Addex Therapeutics Ltd (ADXN) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PYPD carries a Unified Composite Score of 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin), whereas ADXN carries 30.2/100 (SELL) at $3.75 (N/M Forward P/E, -3130.7% operating margin).
Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both PYPD (31.1/100 SELL) and ADXN (30.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
PYPD
NASDAQ
Head-to-Head Winner
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
Market Cap
$132.2M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.89β · 59% Vol
Unified Composite Score
31.1 / 100
SELL
Tech 50.0
Fund 27.0
Flow 56.0
Mom 32.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 63
RSI-14: 63.2 · SMA20: $5.80 · SMA50: $5.40
ADXN
NASDAQ
Addex Therapeutics Ltd American Depositary Shares
Pharmaceutical Preparations
Market Cap
$7.1M
TTM Revenue
$83,069
Forward P/E
N/M
Beta / 30D Vol
2.30β · 308% Vol
Unified Composite Score
30.2 / 100
SELL
Tech 3.0
Fund 40.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 54.8 · SMA20: $3.21 · SMA50: $3.21
6-Pillar Scorecard Institutional Category Breakdown (PYPD 4 – 1 ADXN)
Columns: Metric · PYPD · ADXN
1. Valuation Multiples
ADXN
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
85.7x
2. Growth & Scale
PYPD
Revenue Growth (YoY)
+0.0%
-72.7%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$83,069
Market Cap
$132.2M
$7.1M
3. Profitability & Quality
PYPD
Gross Margin
N/A
N/A
Operating Margin
0.0%
-3130.7%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-243.6%
-150.6%
4. Balance Sheet & Cash Flow
PYPD
Cash Generation (TTM)
N/A
-$2.6M EBITDA
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$5.0M Net Cash
$2.18 Book/Sh · -150.6% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PYPD
Options Structure Phase
BREAKOUT
UNCLASSIFIED
Current IV / %ile
106.3% (12th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
Thin ADR Chain
OBV Trend / Tech Phase
ACCUMULATION · Markup
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: PYPD (6) vs ADXN (1)
Institutional Metric
PYPD
ADXN
Criterion
Row Edge
Market Capitalization
Scale
$132.2M
$7.1M
Larger Scale
PYPD
Trailing P/E Ratio
Valuation
N/M
N/M
Lower Multiple
Tie
Forward P/E Ratio
Valuation
N/M
N/M
Lower Multiple
Tie
Revenue Growth (YoY)
Growth
+0.0%
-72.7%
Higher Growth
PYPD
Operating Margin (TTM)
Profitability
0.0%
-3130.7%
Higher Margin
PYPD
Net Profit Margin
Profitability
0.0%
0.0%
Higher Margin
Tie
Return on Equity (ROE)
Capital Efficiency
-243.6%
-150.6%
Higher ROE
ADXN
52-Week Range Position
Momentum
80% ($4–$7)
13% ($3–$12)
Stronger Trend
PYPD
Beta / 30D Volatility
Risk Regime
0.89β · 59% Vol
2.30β · 308% Vol
Lower Realized Risk
PYPD
Unified Institutional Score
Composite Signal
31.1 / 100 (SELL)
30.2 / 100 (SELL)
Higher Composite
PYPD
Trailing 12M Revenue (USD)
Operating Scale
N/A
$83,069
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A
N/A
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev
N/M PEG · 85.7x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($5.0M Net Cash)
-$2.6M EBITDA ($2.18 Book/Sh · -150.6% ROE)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
PYPD +0.46 pp
PYPD:
+36.33%
·
ADXN:
+35.87%
3M Horizon
PYPD +71.88 pp
PYPD:
+34.91%
·
ADXN:
-36.97%
6M Horizon
PYPD +79.96 pp
PYPD:
+35.76%
·
ADXN:
-44.2%
1Y Horizon
PYPD +134.98 pp
PYPD:
+79.25%
·
ADXN:
-55.73%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PYPD vs ADXN. Trailing 12-month operating profitability (PYPD 0.0% vs ADXN -3130.7%) and valuation multiples (PYPD N/M vs ADXN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
PYPD ADR TTM Benchmark
FX-Normalized USD
TTM Revenue N/A
Gross Margin N/A
Op. Margin 0.0%
ROE / Fwd P/E -243.6% · N/M
ADXN ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $83,069
Gross Margin N/A
Op. Margin -3130.7%
ROE / Fwd P/E -150.6% · N/M
PYPD
BREAKOUT
40d in phase · OBV ACCUMULATION
Current IV
106.3%
IV Percentile
12th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
ADXN
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
Thin ADR Chain
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
PYPD Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ADXN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.1M market capitalization and -3130.7% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ PYPD vs ADXN Key Questions & Quantitative Answers
Is PYPD or ADXN a better stock to buy right now?
As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Addex Therapeutics Ltd (ADXN) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PYPD carries a Unified Composite Score of 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin), whereas ADXN carries 30.2/100 (SELL) at $3.75 (N/M Forward P/E, -3130.7% operating margin). Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both PYPD (31.1/100 SELL) and ADXN (30.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Does PYPD or ADXN have stronger revenue and earnings growth?
PYPD leads the Growth & Scale pillar: PYPD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ADXN at -72.7% YoY revenue growth and +0.0% YoY earnings growth on $83,069 TTM revenue (N/A gross margin, -3130.7% operating margin). On trailing 12-month operating scale, PYPD generates N/A in USD-normalized revenue versus $83,069 for ADXN. In operating R&D and SG&A reinvestment, PYPD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ADXN.
Is PYPD or ADXN cheaper on valuation?
ADXN screens cheaper on headline valuation multiples. PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ADXN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 85.7x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PYPD (-243.6% ROE) versus ADXN (-150.6% ROE) capital efficiency.
How is options market volatility positioned on PYPD vs ADXN?
In options market volatility and institutional positioning, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.89β · 59% Vol realized risk). By comparison, ADXN carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.30β · 308% Vol realized risk).
PolyPid Ltd. Ordinary Shares (PYPD) Research Suite
Addex Therapeutics Ltd American Depositary Shares (ADXN) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.